Related Experiment Videos
Interaction of PtCl4(Fast Black)2 with hyperthermia
B A Teicher1, T S Herman, M R Pfeffer
1Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Research
|November 15, 1989
Summary
New platinum complexes show promise as potent antitumor agents. PtCl4(Fast Black)2 demonstrates enhanced cancer cell killing, particularly when combined with hyperthermia, and exhibits higher intracellular platinum accumulation than cisplatin.
Area of Science:
- Oncology
- Materials Science
- Biochemistry
Background:
- Development of novel platinum-based chemotherapeutics is crucial for overcoming cancer resistance.
- Nuclear dyes offer potential as carriers for platinum complexes, enhancing targeted delivery and efficacy.
Purpose of the Study:
- To investigate the antitumor activity of a novel platinum complex, PtCl4(Fast Black)2, alone and in combination with hyperthermia and/or radiation.
- To evaluate the cellular uptake and efficacy of PtCl4(Fast Black)2 in vitro and in vivo models.
Main Methods:
- In vitro studies using EMT6 cells exposed to PtCl4(Fast Black)2 at varying temperatures and pH.
- Intracellular platinum level measurements comparing PtCl4(Fast Black)2 and cisplatin.
- In vivo studies in FSaIIC murine fibrosarcoma models assessing tumor growth delay with PtCl4(Fast Black)2 and hyperthermia.
Main Results:
- PtCl4(Fast Black)2 exhibited log-linear cell killing in vitro, with efficacy increasing at elevated temperatures (42-43°C) and low pH (6.45), especially under hypoxic conditions.
- Intracellular platinum levels were 170-200 fold higher with PtCl4(Fast Black)2 compared to cisplatin.
- In vivo, PtCl4(Fast Black)2 significantly enhanced tumor growth delay when combined with hyperthermia, outperforming cisplatin in combination therapy.
Conclusions:
- PtCl4(Fast Black)2 is a potent antitumor agent, demonstrating significant activity alone and synergistically with hyperthermia.
- The complex shows favorable pharmacokinetics with high intracellular platinum accumulation.
- PtCl4(Fast Black)2 is a promising candidate for further clinical development as an anticancer drug, potentially in combination with radiation therapy.